BioRestorative Therapies

brtxDISC (DiscImplantedStemCells) is an investigational non-surgical treatment for bulging and herniated lumbar discs that is intended for patients who have failed non-invasive procedures and face the prospect of surgery. The treatment involves culturing a patient's own stem cells and then delivering them via a proprietary medical device to the damaged region of the disc in an outpatient procedure. ThermoStem is a treatment using brown fat stem cells that is under development for metabolic disorders including diabetes and obesity. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. brtx-C Cosmetic is based on the development of a human cellular extract that has been demonstrated in in vitro skin studies to increase the production of collagen and fibronectin, which are proteins that are essential to combating the aging of skin. Potential cosmetic uses are being explored with third parties.
Type
Public
HQ
Melville, US
Founded
1997
Size (employees)
6 (est)
BioRestorative Therapies was founded in 1997 and is headquartered in Melville, US

BioRestorative Therapies Office Locations

BioRestorative Therapies has an office in Melville
Melville, US (HQ)
40 Marcus Dr

BioRestorative Therapies Data and Metrics

BioRestorative Therapies Financial Metrics

BioRestorative Therapies's revenue was reported to be $7 k in Q1, 2017
USD

Revenue (Q1, 2017)

7 k

Net income (Q1, 2017)

(2.8 m)

EBIT (Q1, 2017)

(2.5 m)

Market capitalization (19-Jul-2017)

16.3 m

Closing share price (19-Jul-2017)

3

Cash (31-Mar-2017)

8.9 k
BioRestorative Therapies's current market capitalization is $16.3 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

1.7 k416 k628.9 k36.4 k

Revenue growth, %

24662%51%(94%)

Cost of goods sold

208213.8 k261.5 k102

Gross profit

1.5 k202.2 k367.4 k36.3 k

Gross profit Margin, %

88%49%58%100%

Sales and marketing expense

1.4 m1.6 m

R&D expense

1.4 m2.1 m2.9 m

General and administrative expense

2.3 m3.9 m3.3 m

Operating expense total

5.1 m7.5 m6.1 m

EBIT

(4.8 m)(4.9 m)(7.2 m)(7.8 m)

EBIT margin, %

(282873%)(1183%)(1140%)(21448%)

Interest expense

371.3 k285.3 k263.6 k221.6 k

Net Income

(5.8 m)(5.6 m)(7.9 m)(8.6 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

175.9 k159.9 k184.9 k148.8 k96.1 k9.1 k16.2 k5 k7 k

Cost of goods sold

42.4 k66.1 k76.4 k74.6 k50.9 k1071

Gross profit

133.6 k93.8 k108.5 k74.1 k45.2 k9.1 k16.1 k

Gross profit Margin, %

76%59%59%50%47%100%100%

R&D expense

293.3 k290.7 k406.9 k452.5 k615.6 k866 k608.7 k656.2 k805.9 k

General and administrative expense

548.6 k502.8 k917.6 k696.4 k596.5 k902.9 k982.4 k610.7 k1.2 m

Operating expense total

842 k793.5 k1.3 m1.1 m1.2 m1.8 m1.6 m1.3 m2 m

EBIT

(1.3 m)(896 k)(1.6 m)(1.3 m)(1.5 m)(2.1 m)(2.1 m)(1.7 m)(2.5 m)

EBIT margin, %

(728%)(560%)(879%)(849%)(1550%)(22654%)(13266%)(34304%)(35562%)

Interest expense

72.4 k74.8 k64.6 k60.1 k80.6 k42.8 k45 k57.4 k97.8 k

Net Income

(1.3 m)(1.1 m)(1.8 m)(1.4 m)(1.6 m)(2.5 m)(2.3 m)(1.8 m)(2.8 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

201.1 k91.8 k166.6 k31.8 k

Accounts Receivable

93.4 k6 k

Inventories

18 k1.9 k29.3 k

Current Assets

239.8 k114.3 k289.3 k61.7 k

PP&E

35.6 k493.9 k643.1 k508.6 k

Total Assets

1.4 m1.7 m2 m1.6 m

Accounts Payable

1.3 m1.1 m2.5 m2.3 m

Current Liabilities

7.5 m8.5 m5.6 m5.8 m

Total Liabilities

6.6 m

Additional Paid-in Capital

13.1 m18.5 m29.4 m37 m

Retained Earnings

(25.4 m)(33.3 m)(42 m)

Total Equity

(6.7 m)(6.9 m)(3.9 m)(5 m)

Financial Leverage

-0.2 x-0.2 x-0.5 x-0.3 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

59.2 k374 k145.9 k6.4 k12.8 k353.1 k516.2 k6.3 k8.9 k

Accounts Receivable

51 k9 k16 k5 k7 k

Inventories

17.8 k17.4 k1.9 k2.5 k2.5 k

Current Assets

95 k421.5 k180.2 k246.1 k385 k384.2 k546.2 k32.6 k38.2 k

PP&E

18.3 k73.6 k537.2 k702.3 k662.5 k599.4 k602.4 k555.6 k463 k

Total Assets

1.2 m1.6 m1.9 m2.1 m2.2 m2 m2.2 m1.6 m1.5 m

Accounts Payable

893.4 k774.1 k1.3 m1.7 m2.1 m2.2 m2.1 m2 m2.3 m

Current Liabilities

8.3 m7.4 m8.9 m4.9 m5.5 m5.6 m5.7 m5.5 m6.1 m

Additional Paid-in Capital

15.7 m17.5 m19.8 m25.7 m26.5 m32.3 m34.1 m35.4 m40 m

Retained Earnings

(22.8 m)(23.9 m)(27.2 m)(28.6 m)(30.2 m)(35.8 m)(38.1 m)(39.9 m)(44.7 m)

Total Equity

(7.1 m)(6.5 m)(7.4 m)(2.9 m)(3.8 m)(3.5 m)(4 m)(4.5 m)(4.7 m)

Financial Leverage

-0.2 x-0.2 x-0.3 x-0.7 x-0.6 x-0.6 x-0.5 x-0.4 x-0.3 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(5.6 m)(7.9 m)(8.6 m)

Depreciation and Amortization

96.7 k213.8 k258.4 k

Accounts Receivable

(93.4 k)87.4 k

Inventories

613(6.8 k)

Accounts Payable

(234.6 k)1.4 m(113.2 k)

Cash From Operating Activities

(3.2 m)(3.1 m)(5 m)

Purchases of PP&E

(168.4 k)(408.1 k)(188.8 k)

Cash From Investing Activities

(167.4 k)(483.1 k)(188.8 k)

Cash From Financing Activities

3.3 m3.7 m5.1 m

Interest Paid

127.1 k61.5 k30.4 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(1.3 m)(1.1 m)(1.8 m)(1.4 m)(1.6 m)(2.5 m)(2.3 m)(1.8 m)(2.8 m)

Accounts Receivable

51 k9 k16 k5 k7 k

Inventories

17.8 k17.4 k1.9 k2.5 k2.5 k

Accounts Payable

893.4 k774.1 k1.3 m1.7 m2.1 m2.2 m2.1 m2 m2.3 m
Y, 2017

Financial Leverage

-0.3 x

BioRestorative Therapies Market Value History

Traffic Overview of BioRestorative Therapies

BioRestorative Therapies Company Life and Culture

You may also be interested in